You can contact us

Russia is preparing a legal basis for gene therapy developed for a specific patient

Published 14 November 2026
Last update 16 November 2026
2
On November 11, 2026, the State Duma Committee on Health Protection recommended adopting in the first reading bill No. 12837-9, which provides for the manufacture and use of individual gene therapy medicinal products without state registration. The document has not yet been adopted.

🏥 What is proposed to be permitted
A medical organization will be able to manufacture a medicinal product for a specific patient under an individual prescription and use it in the same clinic. Only medical organizations that have received a special permit will be able to operate under this procedure.

Somatic cell-based products and tissue engineering products are excluded from the proposed definition of individual gene therapy medicinal products.

🔬 How control will be ensured
The bill provides for regulation of the entire circulation of such a medicinal product: development, preclinical studies, expert reviews, manufacturing, quality control, and use.

An ethics council will assess the ethical justification for the manufacture and use of individual therapy.
Roszdravnadzor will monitor its efficacy and safety in order to identify possible negative consequences.

⚖️ What conditions still need to be established
Specific rules are to be defined in subordinate legislation. They will establish:
— requirements for medical organizations;
— the procedure for manufacturing medicinal products, conducting expert reviews, and quality control;
— rules for use, storage, transportation, and destruction;
— the conditions for issuing, confirming, and revoking permits, as well as maintaining their register.

Thus, the bill sets out the legal framework, while the practical operation of the mechanism will depend on subsequent regulation. These provisions are set out in the text of the draft prepared for the first reading.

🌍 Russian and international context
Russia already has a special permitting procedure for individual biomedical cell products (BMCPs). The new bill provides for a separate regime for individual gene therapy medicinal products. Russian Government Resolution No. 385.

In the EU, similar tasks are addressed through the "hospital exemption" for advanced therapy medicinal products, including gene therapy, cell therapy, and tissue engineering. The mechanism involves a national authorization for the manufacture of a medicinal product on a non-routine basis and its use in a hospital within a single EU country for a specific patient. An example is the academic CAR-T therapy ARI-0001, developed by Hospital Clínic Barcelona and authorized by the Spanish regulator. European Commission, AEMPS.

In the USA, the use of an investigational medicinal product in a single patient is possible under FDA oversight through a single-patient IND within the framework of expanded access (expanded access). This mechanism is used for serious diseases when there are no satisfactory treatment alternatives. FDA.

There are already precedents for personalized development, including genome editing for CPS1 deficiency in 2025. This experience demonstrates the possibility of creating therapy for a specific patient mutation while maintaining regulatory control. Publication by researchers.

📅 Further stages
The first reading is proposed to be held on November 17, and the deadline for submitting amendments is recommended to be set until December 7, 2026.
In the current version of the draft, the law is envisaged to enter into force on March 1, 2028, if it is adopted in this form.

📎 Source: bill No. 12837-9 and State Duma documents.
Russia is preparing a legal basis for gene therapy developed for a specific patient
Select language
Your message has been sent successfully!
We will contact you shortly. If you have an urgent question, please call us at 8 903 663 25 20 or write to us at musinan@orphan-cis.net.

Your opinion is important to us!